Precision in the Crosshairs: India’s First Approved Radioligand Therapy for Advanced Prostate Cancer

Novartis introduces Pluvicto, a breakthrough targeted therapy that marks a shift in how India tackles hard-to-treat metastatic prostate cancer.

For thousands of Indian men, a prostate cancer diagnosis often carries the weight of a terminal prognosis, primarily because the disease is frequently detected only after it has begun its aggressive spread. With more than half of all cases in the country reaching the metastatic stage before clinical intervention, the medical community has long been searching for tools that go beyond standard systemic care. This week, that landscape shifted as Novartis launched Pluvicto in India, the country’s first regulatory-approved radioligand therapy designed specifically for advanced, PSMA-positive metastatic castration-resistant prostate cancer.

How Pluvicto works

At its core, this treatment functions like a biological heat-seeking missile. Unlike traditional chemotherapy, which often affects both healthy and malignant cells, radioligand therapy combines a targeting molecule—a ligand—with a therapeutic radioisotope. Once injected intravenously, the drug identifies and binds to the Prostate-Specific Membrane Antigen (PSMA), a protein overexpressed on the surface of these cancer cells. By delivering radiation directly to the tumor site, the therapy minimizes collateral damage to surrounding healthy tissue, offering a more refined approach to oncology.

The clinical data backing this arrival is significant. Global Phase III trials indicated that the therapy not only reduces the risk of disease progression but also lowers the risk of fatal outcomes compared to standard treatments. For patients, the promise isn't just about survival rates; it is about maintaining a better quality of life during the rigorous course of treatment. The medication, which is imported from specialized facilities in Spain and Italy, is now officially entering a market where the disease burden is rising rapidly.

The burden of prostate cancer in India

The arrival of such high-end precision medicine comes at a critical juncture. According to data from the ICMR-National Institute of Cancer Prevention and Research (NICPR), prostate cancer is now among the top three cancers affecting men in urban India, ranking second in major metros like Delhi, Pune, Kolkata, and Thiruvananthapuram. With roughly 2.5 lakh new cases identified annually, the statistics are sobering: while the overall five-year survival rate is 64 percent, that figure plummets to a mere 30 percent once the disease reaches Stage IV, spreading to bones, lymph nodes, or the bladder.

Why it matters

The launch of Pluvicto is a clear indicator of the "precision oncology" shift within India’s private healthcare sector. For years, the country has relied heavily on conventional, blunt-force treatment methods for late-stage cancers. Bringing in radioligand therapy suggests that global pharmaceutical players are seeing India as a viable hub for specialized, high-cost, and high-efficacy medical interventions. However, the true test will be the accessibility of such advanced therapies. While this is a major scientific step forward for oncology, the challenge for the domestic health system will be ensuring that these life-extending innovations reach the broader population, rather than remaining limited to elite urban centers.